OakChart

Geovax Labs Inc

GOVXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:58 PM ET

2.16-0.52 (-19.28%)
2026-11-12 03:46 CET
Market cap
26.37 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-20.43 USD m
Free cash flow, TTM
-18.37 USD m
EPS diluted, TTM
-13.93
P/E
-
Compare

Price

GOVX against its 20, 50 and 200-day averages
2050200earnings
0.0050.00100.00150.00200.004.4M8.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GOVXclose 2.1620-day 4.4550-day 7.13200-day 27.522.16

99.3% under the 52-week high of 311.94 on 12 Nov 2025. 52-week low 1.84 on 11 Nov 2026. Last 15 sessions, 199.9% high to low

Volume 15.04× normal · the line is the 50-bar volume average

Profile

GOVX
52-week range, 0% of the way up
2.66311.94

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola-Zaire, Ebola-Sudan, Lassa, Marburg, Zika virus and malaria. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Employees19
IPOMay 12, 1997
Beta3.89
ATR, 14d0.68
Rel volume15.04
Short float1.44%
Insider own0.03%
Inst own4.38%

Snapshot

6 groups

Valuation

Index-
Market Cap1.10M
Enterprise Value-1.72M
Income-20.43M
Sales0.00M
Book/sh5.73
Cash/sh6.16
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees19
IPOMay 12, 1997

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.38
P/C0.35
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.54
Current Ratio1.54
Debt/Eq0.18
LT Debt/Eq0.10
Option/ShortNo / Yes

Earnings

EPS (ttm)-334.26
EPS next Y-63.36
EPS next Q-26.16
EPS this Y77.05%
EPS next Y48.64%
EPS next 5Y-
EPS past 3/5Y58.34% 51.11%
Sales past 3/5Y- 6.42%
EPS Y/Y TTM77.63%
Sales Y/Y TTM-100.00%
EPS Q/Q88.91%
Sales Q/Q-100.00%
EarningsAug 12
EPS/Sales Surpr.19.17% -

Ownership

Insider Own0.03%
Insider Trans0.00%
Inst Own4.38%
Inst Trans5.91%
ROA-408.80%
ROE-891.59%
ROIC-1058.19%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-51.42%
SMA50-69.69%
SMA200-92.15%
Trades-

Technical

Shs Outstand0.51M
Shs Float0.51M
Short Float1.44%
Short Ratio0.21
Short Interest0.01M
52W High311.94 -99.31%
52W Low2.66 -18.74%
Volatility28.47% 14.73%
ATR (14)0.68
RSI (14)11.45
Beta3.89
Rel Volume15.04
Avg Volume34.55K
Volume519,739

Performance

Perf Week-46.43%
Perf Month-66.11%
Perf Quarter-87.46%
Perf Half Y-93.08%
Perf YTD-97.89%
Perf Year-99.27%
Perf 3Y-99.95%
Perf 5Y-99.99%
Perf 10Y-100.00%
Recom1.00
Target Price240.00
Prev Close2.68
Price2.16
Change %-19.28%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Feb 19, 2026DowngradeDD. Boral CapitalBuy → Hold
Apr 15, 2025ReiteratedDD. Boral CapitalBuy$18 → $14+548.1%
Apr 15, 2025ReiteratedAAlliance Global PartnersBuy$15 → $8.50+293.5%
Nov 11, 2024InitiatedAAlliance Global PartnersBuy$15+594.4%
Jul 16, 2024InitiatedRROTH MKMBuy$20+825.9%
Nov 19, 2020InitiatedMMaxim GroupBuy$8+270.4%

Peers

Mkt cap
TickerCompanyMkt cap
INOInovio Pharmaceuticals Inc152.51M
NVAXNovavax Inc1.65B
EVAXEvaxion A/S ADR24.27M
VALNValneva SE ADR563.17M
SCNIScinai Immunotherapeutics Ltd ADR0.69M
AIMAIM ImmunoTech Inc5.93M
ARCTArcturus Therapeutics Holdings Inc268.33M
DCOYDecoy Therapeutics Inc2.60M
CADLCandel Therapeutics Inc705.50M
NNVCNanoViricides Inc35.23M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-23.280-28.800-23.2800.000.002
2026Q12026-04-30-62.880-124.2-62.8800.000.002
2025Q42026-03-26-54.960-112.96-61.2240.000.003
2025Q32025-11-13-186-140.46-186.890.000.002
2025Q22025-08-06-210-208.5-209.760.880.784
2025Q12025-05-01-270-394.5-268.91.621.674
2024Q42025-03-27-525.42-481.5-470.50.882.974
2024Q32024-11-12-546-789.6-544.82.791.345
2024Q22024-08-06-1,194-2,019-1,1960.300.004
2024Q12024-05-14-1,482-3,336-1,4830.000.001
2023Q42024-02-29-2,364-1,666-2,3190.000.003
2023Q32023-11-08-2,880-1,823-2,8510.000.004
2023Q22023-08-09-1,980-1,485-2,0170.000.004
2023Q12023-05-04-1,350-1,830-1,3800.000.003
2022Q42023-03-23-1,260-1,800-1,8400.000.003
2022Q32022-11-09-1,530-1,080-1,5220.000.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-3,600,000,000-3,600,000,000-2,817,000,0070.960.90
2020FY-19,260-2,430-19,2381.821.97
2021FY-27,360-10,620-27,3990.390.22
2022FY-7,470-6,953-7,4350.080.09
2023FY-8,574-5,904-8,5730.000.00
2024FY-2,892-2,880-2,8913.965.32
2025FY-537.626.400-28.8002.502.50
2026FY--123.36--0.00
2027FY--63.360---
2028FY--71.040---
2029FY-102.96--112.42
2030FY-176.4--196.74

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-031000.000.000.00
2026Q3S2026-08-122000.000.000.00
2026Q3S2026-04-302000.000.000.00
2026Q3S2026-04-172000.000.000.00
2026Q3S2026-03-261000.000.000.00
2026Q3S2025-11-142000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-042000.000.000.00

Estimate history

EPS, annual-225000000.563-117375000.293-294300-801.6-1141.631-309.776-357.221-120.456-22.396-334.2576
Period201720182019202020212022202320242025TTM
EPS, quarterly-49.845-22.7-19.604-11.204-8.74-7.787-2.551-2.62-0.97
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual1.0750.9631.1761.8240.386003.9552.4890
Period201720182019202020212022202320242025TTM
Sales, quarterly0.3012.7890.8641.6370.8520000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0000.010.0170.070.0790.4211.7327.369
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.1670.3440.4210.5540.6371.1881.7322.8197.369
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.002.493.950.000.000.391.821.180.96
Cost of Goods Sold Incl. D&A0.060.070.100.070.06----
Gross Profit-0.062.423.86-0.07-0.06----
Selling, General and Administrative Excl. Other20.4724.0629.0026.6714.0519.094.623.543.51
Research and Development15.0518.1223.7120.729.1215.552.441.911.88
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-20.53-21.64-25.14-26.74-14.11-18.75-2.82-2.37-2.56
Interest Expense0.000.000.020.00-0.000.140.000.00
Unusual Expense0.000.000.000.000.00-0.170.00--
Net Income Before Taxes-20.43-21.46-24.99-25.97-14.02-18.57-2.96-2.37-2.56
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-20.43-21.46-24.99-25.97-14.02-18.57-2.96-2.37-2.56
Net Income From Continuing Operations-20.43-21.46-24.99-25.97-14.02-18.57-2.96-2.37-2.56
Net Income-20.43-21.46-24.99-25.97-14.02-18.57-2.96-2.37-2.56
EPS (Recurring)-4.47-22.40-120.46-357.22-309.78-1,149.03-801.60-294,356.44-117,381,659.79
EPS (Basic, Before Extraordinaries)-13.93-22.40-120.46-357.22-309.78-1,141.63-801.60-294,300.00-117,375,000.29
EPS (Diluted)-13.93-22.40-120.46-357.22-309.78-1,141.63-801.60-294,300.00-117,375,000.29
EBITDA-20.47-21.57-25.05-26.67-14.05-18.71-2.80-2.36-2.54
Non-Operating Income (Expense)0.100.170.170.780.090.000.000.010.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.911.120.470.860.900.370.060.100.16
Price To Sales Ratio-1.653.24--57.282.560.034.08
Gross Margin-97.2497.59------
Operating Margin--869.34-635.83---4,862.72-154.46-201.76-266.06
Net Margin--862.34-631.98---4,817.19-162.21-201.60-265.79
Shares Outstanding7.371.730.420.080.070.020.010.000.00
Market Capitalization26.3726.37624.63231.29398.31554.43311.024.32126.10

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.851.640.862.79
Cost of Goods Sold Incl. D&A0.010.010.020.02-0.020.020.03
Gross Profit-0.01-0.01-0.02-0.02-1.620.842.76
Selling, General and Administrative Excl. Other4.435.264.426.366.257.039.198.61
Research and Development3.113.902.995.044.735.357.617.40
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.44-5.27-4.44-6.37-5.42-5.41-8.34-5.85
Interest Expense0.000.000.000.000.000.00-0.01
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-4.43-5.26-4.42-6.32-5.37-5.36-8.26-5.82
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.43-5.26-4.42-6.32-5.37-5.36-8.26-5.82
Net Income From Continuing Operations-4.43-5.26-4.42-6.32-5.37-5.36-8.26-5.82
Net Income-4.43-5.26-4.42-6.32-5.37-5.36-8.26-5.82
EPS (Recurring)-0.97-2.62-2.55-7.79-8.74-11.20-19.60-22.70
EPS (Basic, Before Extraordinaries)-0.97-2.62-2.55-7.79-8.74-11.20-19.60-22.70
EPS (Diluted)-0.97-2.62-2.55-7.79-8.74-11.20-19.60-22.70
EBITDA-4.43-5.26-4.42-6.36-5.40-5.39-8.32-5.82
Non-Operating Income (Expense)0.020.010.020.050.050.050.080.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.160.220.250.280.290.290.090.13
Price To Sales Ratio-3.252.972.862.162.276.585.00
Gross Margin-----98.9797.5098.91
Operating Margin-----635.81-330.22-965.32-209.88
Net Margin-----630.05-327.31-955.87-208.48
Shares Outstanding7.372.821.731.190.640.550.420.34
Market Capitalization26.3773.64177.72337.29330.86352.08624.63497.96

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.095.516.4527.6111.429.880.280.260.31
Short Term Receivables0.000.660.000.000.050.180.070.120.06
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.231.771.431.330.160.170.100.240.08
Total Current Assets5.317.937.8928.9411.6310.240.450.620.45
Net Property, Plant & Equipment0.940.150.210.230.160.150.010.010.03
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets42.92--------
Other Assets0.090.071.192.170.010.010.010.010.01
Total Assets49.268.169.2831.3511.8010.390.470.640.49
Short Term Debt Incl. Current Port. of LT Debt0.260.000.000.000.000.180.010.260.00
Accounts Payable0.791.852.801.752.060.270.150.130.08
Other Current Liabilities0.881.260.723.003.380.361.851.240.73
Total Current Liabilities1.943.113.524.755.440.812.021.620.81
Long Term Debt0.580.000.000.000.000.010.030.040.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities42.92--------
Other Liabilities0.000.000.000.002.000.000.000.000.00
Total Liabilities45.443.113.524.757.440.832.041.660.81
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.081.931.971.90
Common Equity3.835.055.7626.604.369.49-3.51-2.99-2.22
Total Shareholders Equity3.835.055.7626.604.369.57-1.57-1.02-0.32
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity3.835.055.7626.604.369.57-1.57-1.02-0.32
Total Liabilities & Stockholders Equity49.268.169.2831.3511.8010.390.470.640.49
Book Value Per Share2.2111.9872.87378.77256.31928.45-87,722.97-102,558,410.41-156,018,411.81
Tangible Book Value Per Share2.2111.9872.87378.77256.31928.45-87,722.97-102,558,410.41-156,018,411.81
Full-Time Employees19171714119699
Price to Book Ratio9.04123.7225.3612.53127.1132.76-1.23-42.12-39.16
Return on Assets-74.77-286.62-127.82-65.00-167.37-54.46-426.78-452.19-394.41
Return on Equity-483.79-462.31-160.47-90.57-266.61-74.00---
Return on Invested Capital-487.26-495.04-450.55-52.71-425.76-30.87---
Quick Ratio2.742.552.246.102.1412.630.220.380.55
Current Ratio2.742.552.246.102.1412.630.220.380.55

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-20.43-21.46-24.99-25.97-14.02-18.57-2.96-2.37-2.56
Depreciation0.060.070.100.070.060.040.020.010.02
Other Funds (Non Cash)0.911.120.531.070.900.410.190.330.47
Funds from Operations-19.45-20.28-24.37-24.82-13.06-18.12-2.75-2.03-2.07
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.08-1.19-0.31-0.36-5.976.93-0.000.640.53
Cash from Operating Activities-18.37-21.47-24.68-25.17-19.03-11.20-2.75-1.40-1.54
Capital Expenditures0.00-0.03-0.02-0.05-0.13-0.05-0.16-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.00-0.03-0.02-0.05-0.13-0.05-0.16-0.010.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.4219.0823.774.0635.3512.8111.461.441.19
Repurchase of Common Pref Stock0.000.000.000.000.00-0.000.000.000.00
Sale of Common Pref Stock18.4219.0823.774.0635.3512.8111.461.441.19
Proceedsfrom Stock Options18.9218.9221.400.0027.739.4111.461.441.19
Issuance or Reduction of Debt, Net0.000.00-0.010.000.00-0.031.05-0.010.30
Change in Long Term Debt0.000.000.000.000.00-0.031.05-0.010.30
Issuance of Long Term Debt0.000.000.000.000.000.001.060.000.30
Reduction of Long Term Debt0.000.000.000.000.00-0.03-0.01-0.010.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities18.4219.0823.754.0635.3512.7812.511.431.49
Net Change in Cash0.05-2.42-0.95-21.1616.191.549.600.02-0.05
Free Cash Flow-18.37-21.50-24.70-25.22-19.16-11.24-2.91-1.41-1.54
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments3.141.273.095.013.097.44
Short Term Receivables0.000.000.000.000.531.50
Inventories0.000.000.000.000.000.00
Other Current Assets1.031.162.231.511.511.68
Total Current Assets4.182.435.316.525.1410.61
Net Property, Plant & Equipment0.400.480.940.130.140.15
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--42.92---
Other Assets0.070.070.090.090.070.07
Total Assets4.642.9849.266.735.3510.83
Short Term Debt Incl. Current Port. of LT Debt0.150.200.260.000.000.00
Accounts Payable1.831.430.790.981.832.40
Other Current Liabilities0.720.660.880.850.700.53
Total Current Liabilities2.712.291.941.822.532.94
Long Term Debt0.170.200.580.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--42.92---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.882.4945.441.822.532.94
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1.760.493.834.912.827.90
Total Shareholders Equity1.760.493.834.912.827.90
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1.760.493.834.912.827.90
Total Liabilities & Stockholders Equity4.642.9849.266.735.3510.83
Book Value Per Share0.240.182.214.134.4314.27
Tangible Book Value Per Share0.240.182.214.134.4314.27
Full-Time Employees--19---
Price to Book Ratio9.048.0246.4668.73117.2844.58
Return on Assets-408.80-309.34-74.77-283.68-525.24-345.27
Return on Equity-891.59-509.28-483.79-377.44-9,690.24-616.17
Return on Invested Capital-229.32-761.63-100.30-128.77-190.34-67.84
Quick Ratio1.541.062.743.572.033.62
Current Ratio1.541.062.743.572.033.62

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.43-5.26-4.42-6.32-5.37-5.36
Depreciation0.010.010.020.020.020.02
Other Funds (Non Cash)0.160.220.250.280.290.29
Funds from Operations-4.25-5.03-4.15-6.02-5.06-5.05
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.591.49-0.81-0.190.73-0.92
Cash from Operating Activities-3.66-3.54-4.96-6.21-4.33-5.97
Capital Expenditures0.000.000.000.00-0.01-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.00-0.01-0.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock5.531.723.048.130.007.91
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.531.723.048.130.007.91
Proceedsfrom Stock Options0.000.0018.920.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities5.531.723.048.130.007.91
Net Change in Cash1.87-1.81-1.921.92-4.341.93
Free Cash Flow-3.66-3.54-4.96-6.21-4.35-5.98

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 3.95M 2025: 2.49M
United States2024: 3.95M 2025: 2.49M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.74%0.0M0.4M31.92K
2026-10-152.68%0.0M0.4M32.26K
2026-09-302.79%0.0M0.4M23.72K
2026-09-154.94%0.0M0.4M25.20K
2026-08-314.04%0.0M0.4M30.89K
2026-08-142.47%0.0M0.3M207.41K
2026-07-310.80%0.0M0.3M212.01K
2026-07-152.96%0.0M0.2M214.61K
2026-06-301.25%0.0M0.2M209.94K
2026-06-155.41%0.0M0.2M204.34K
2026-05-2917.60%0.0M0.1M199.50K
2026-05-1514.18%0.0M0.1M9.61K
2026-04-308.80%0.0M0.1M4.38K
2026-04-159.60%0.0M0.1M4.86K
2026-03-3111.40%0.0M0.1M5.81K
2026-03-1311.96%0.0M0.1M7.15K
2026-02-279.49%0.0M0.1M6.74K
2026-02-1315.76%0.0M0.1M5.85K
2026-01-3018.70%0.0M0.1M5.13K
2026-01-158.81%0.0M0.1M3.94K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-05SEC
2026-11-068-KCurrent report2026-11-05SEC
2026-11-04S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-11-033Initial statement of beneficial ownership of securities2026-10-25SEC
2026-11-033Initial statement of beneficial ownership of securities2026-10-25SEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-278-KCurrent report2026-10-23SEC
2026-10-27DRS/ASEC
2026-09-23EFFECTEffectiveness filing by commission orderSEC
2026-09-17S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-09-10DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-27SEC
2026-09-108-KCurrent report2026-09-10SEC
2026-08-31PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-27SEC
2026-08-288-KCurrent report2026-08-27SEC
2026-08-288-KCurrent report2026-08-25SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-10SCHEDULE 13G/ASEC
2026-07-30DRSSEC
2026-07-2710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-278-KCurrent report2026-07-27SEC
2026-07-108-KCurrent report2026-07-07SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC6.05%
HRT FINANCIAL LP2.43%
StoneX Group Inc.0.21%
GEODE CAPITAL MANAGEMENT, LLC0.21%
TWO SIGMA SECURITIES, LLC0.21%
Universal- Beteiligungs- und Servicegesellschaft mbH0.20%
VANGUARD FIDUCIARY TRUST CO0.10%
Tower Research Capital LLC0.07%
VANGUARD CAPITAL MANAGEMENT LLC0.06%
MORGAN STANLEY0.04%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.26%
VANGUARD EXTENDED MARKET INDEX FUND0.06%
Fidelity Series Total Market Index Fund0.01%
Fidelity Total Market Index Fund0.01%

OakChart. GOVX. Cached 15 minutes.

Some panels did not load: insider.